Cargando…

Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study

OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was...

Descripción completa

Detalles Bibliográficos
Autores principales: Da Silva, Lila Morena Bueno, Rathore, Upendra, Agarwal, Vikas, Gupta, Latika, Shinjo, Samuel Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish League Against Rheumatism 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791548/
https://www.ncbi.nlm.nih.gov/pubmed/36589603
http://dx.doi.org/10.46497/ArchRheumatol.2022.9108
_version_ 1784859430207094784
author Da Silva, Lila Morena Bueno
Rathore, Upendra
Agarwal, Vikas
Gupta, Latika
Shinjo, Samuel Katsuyuki
author_facet Da Silva, Lila Morena Bueno
Rathore, Upendra
Agarwal, Vikas
Gupta, Latika
Shinjo, Samuel Katsuyuki
author_sort Da Silva, Lila Morena Bueno
collection PubMed
description OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was conducted at two tertiary rheumatology centers (one in Brazil and one in India) between January 2000 to January 2020 included a total of 115 patients with ASSD (21 males, 94 females; mean age; at disease diagnosis at 40.3; range, 18 to 80 years). Demographic, clinical and laboratory data of the patients were recorded. Clinical involvement was evaluated. RESULTS: Of the patients, 81 were Brazilians and 34 were of Indian origin. The Indian group exhibited a greater delay in diagnosis after the onset of symptoms compared to Brazilian patients (12 vs. 6 months, respectively; p=0.026). Brazilian patients exhibited a significantly higher prevalence of joint and lung involvement, mechanic’s hands, and Raynaud’s phenomenon. Anti-Jo-1 was the most common autoantibodies in both groups. Systemic arterial hypertension, followed by diabetes mellitus were the most prevalent comorbidities. Concerning previously used drugs, the Indian patients had a larger group of patients treated with antimalarials, whereas the Brazilian group used more azathioprine and intravenous immunoglobulin. A higher proportion of Indian patients was treated with one immunosuppressive drug (70.6%), while the Brazilian group were often treated using two immunosuppressive drugs (33%). Comparison between the severity and prognosis showed that Brazilian group had a higher number of relapses, and during follow-up, the global mortality rates were similar in both groups (6.2% for Brazilian vs. 8.8% for Indian). CONCLUSION: Brazilian and Indian patients with ASSD have comparable epidemiological characteristics such as age at the time of disease diagnosis, and sex distribution, and autoantibodies. Diagnostic delay is seen in Indian patients, and Brazilians exhibit a higher prevalence of joint and lung involvement, mechanic’s hands, Raynaud’s phenomenon with a higher number of relapses, although the mortality rate seems to be similar in both groups.
format Online
Article
Text
id pubmed-9791548
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Turkish League Against Rheumatism
record_format MEDLINE/PubMed
spelling pubmed-97915482022-12-30 Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study Da Silva, Lila Morena Bueno Rathore, Upendra Agarwal, Vikas Gupta, Latika Shinjo, Samuel Katsuyuki Arch Rheumatol Original Article OBJECTIVES: To compare clinical, demographic, laboratory data, prognostic and treatment characteristics of patients with antisynthetase syndrome (ASSD) treated in two different centers of India and Brazil. PATIENTS AND METHODS: This international, two-center, retro-prospective cohort study which was conducted at two tertiary rheumatology centers (one in Brazil and one in India) between January 2000 to January 2020 included a total of 115 patients with ASSD (21 males, 94 females; mean age; at disease diagnosis at 40.3; range, 18 to 80 years). Demographic, clinical and laboratory data of the patients were recorded. Clinical involvement was evaluated. RESULTS: Of the patients, 81 were Brazilians and 34 were of Indian origin. The Indian group exhibited a greater delay in diagnosis after the onset of symptoms compared to Brazilian patients (12 vs. 6 months, respectively; p=0.026). Brazilian patients exhibited a significantly higher prevalence of joint and lung involvement, mechanic’s hands, and Raynaud’s phenomenon. Anti-Jo-1 was the most common autoantibodies in both groups. Systemic arterial hypertension, followed by diabetes mellitus were the most prevalent comorbidities. Concerning previously used drugs, the Indian patients had a larger group of patients treated with antimalarials, whereas the Brazilian group used more azathioprine and intravenous immunoglobulin. A higher proportion of Indian patients was treated with one immunosuppressive drug (70.6%), while the Brazilian group were often treated using two immunosuppressive drugs (33%). Comparison between the severity and prognosis showed that Brazilian group had a higher number of relapses, and during follow-up, the global mortality rates were similar in both groups (6.2% for Brazilian vs. 8.8% for Indian). CONCLUSION: Brazilian and Indian patients with ASSD have comparable epidemiological characteristics such as age at the time of disease diagnosis, and sex distribution, and autoantibodies. Diagnostic delay is seen in Indian patients, and Brazilians exhibit a higher prevalence of joint and lung involvement, mechanic’s hands, Raynaud’s phenomenon with a higher number of relapses, although the mortality rate seems to be similar in both groups. Turkish League Against Rheumatism 2022-03-03 /pmc/articles/PMC9791548/ /pubmed/36589603 http://dx.doi.org/10.46497/ArchRheumatol.2022.9108 Text en Copyright © 2022, Turkish League Against Rheumatism https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
Da Silva, Lila Morena Bueno
Rathore, Upendra
Agarwal, Vikas
Gupta, Latika
Shinjo, Samuel Katsuyuki
Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title_full Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title_fullStr Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title_full_unstemmed Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title_short Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study
title_sort demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: an international, two-center cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791548/
https://www.ncbi.nlm.nih.gov/pubmed/36589603
http://dx.doi.org/10.46497/ArchRheumatol.2022.9108
work_keys_str_mv AT dasilvalilamorenabueno demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy
AT rathoreupendra demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy
AT agarwalvikas demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy
AT guptalatika demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy
AT shinjosamuelkatsuyuki demographicclinicallaboratorydataprognosticandtreatmentfeaturesofpatientswithantisynthetasesyndromeaninternationaltwocentercohortstudy